Neuroimaging

Amnestic mild cognitive impairment individuals with dissimilar pathologic origins show common regional vulnerability in the default mode network

Swati Rane a,*, Manus J. Donahue b,c,d, Daniel O. Claassen b

aRadiology, University of Washington Medical Center, Nashville, TN, USA
bNeurology, Vanderbilt University Medical Center, Nashville, TN, USA
cRadiology, Vanderbilt University Medical Center, Nashville, TN, USA
dPsychiatry, Vanderbilt University Medical Center, Nashville, TN, USA

Abstract

Introduction: Alzheimer’s and Parkinson’s disease (AD and PD) are distinct disorders but share similar biomarker profiles. The regions of the default mode network are implicated in these diseases and are associated with amnestic symptoms. The role of apolipoprotein-ε4 (APOE-ε4), which is associated with cognitive function, is unclear in PD.

Methods: In this work, we evaluated cortical thickness of default mode network regions that are likely affected in both early AD and PD individuals, that is, with amnestic mild cognitive impairment. We identified the prevalence of APOE-ε4 and evaluated its association with cortical atrophy.

Results: We observed significant parahippocampal atrophy and hippocampal atrophy rates in amnestic mild cognitive impairment subjects, regardless of disease origins (AD or PD). Similarly, mild cognitive impairment ε4 carriers showed significant precuneal atrophy compared with noncarriers.

Discussion: This work supports that converging changes to default mode network regions, especially the temporal lobe and precuneus, are shared in AD and PD.

© 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Default mode network; MCI; Alzheimer’s disease; Parkinson’s disease; Cortical thickness; FSL; FreeSurfer

1. Introduction

Despite the clinical distinctions between Alzheimer’s disease (AD) and Parkinson’s disease (PD), these disorders share similar clinicopathologic features [1–4]. In both, cognitive symptoms worsen over time, where early symptoms of mild cognitive impairment (MCI) can progress to dementia. Amnestic mild cognitive impairment (aMCI) is considered an early clinical symptom in AD pathology, and in PD, early executive dysfunction is followed by deficits to visual spatial and memory domains [5]. However, there exists substantial individual variation in the type of cognitive presentation and rate and extent of progression.

The apolipoprotein-ε4 (APOE-ε4) allele is a genetic risk factor that may contribute to the manifestation of amnestic symptoms in both disorders. Individuals with a heterozygous-ε4 allele have a 47% increased risk of developing AD, whereas those with a homozygous-ε4 allele have a 91% increased risk [6,7]. Healthy older adults with an APOE-ε4 allele require an increased area of cortical activity during cognitive tasks, suggesting a genetic link to neuropathological changes that precede cognitive symptoms [8]. More so, APOE-ε4 appears to account for memory-related cognitive dysfunction in PD [9,10], similar to that seen in aMCI attributed to AD pathology. Patients with PD with an ε4 allele have higher odds of
developing dementia, lower scores on the Clinical Dementia Rating scale, and reduced episodic memory performance [6,11,12]. However, the causative role of APOE-ε4 on the development of PD-related dementia is still unknown, as some studies report a lack of association between the APOE-ε4 allele and PD-related dementia [13,14].

Advancing AD is accompanied by progressive neuropathological accumulation of β-amyloid and tau protein aggregates, whereas increased α-synuclein deposition, or Lewy bodies, accumulates in PD. In vivo cerebral spinal fluid (CSF) measures of β-amyloid (Aβ42), tau, and α-synuclein can inform concomitant neuropathologic accumulation in brain parenchyma, where reduced CSF levels of β-amyloid (Aβ42) appear quite reliable in assessing concomitant brain amyloid aggregation [15]. Indeed, β-amyloid (Aβ42) is a well-described contributor to disease pathologic progression of AD and reduced levels inform the risk of progression from aMCI to AD [16,17].

Brain regions of the default mode network appear vulnerable to β-amyloid accumulation, especially in APOE-ε4 carriers [18,19], and symptoms of aMCI localize to this network. These regions include the posterior cingulate, medial frontal, and lateral parietal cortices, and disease-relevant changes to this network are evident in both AD and PD [20–22]. In AD, reduced connectivity between the hippocampus and the posterior cingulate accounts for aMCI presentation [21,23,24]. Likewise, patients with PD have reduced connectivity between the posterior cingulate and medial prefrontal regions [22], and this appears responsive to dopamine therapy [25,26]. A limited number of studies have investigated the association between APOE-ε4 and the default mode network region in PD either with respect to functional or structural integrity.

In this study, we compare morphometric measurements in the default mode network regions (no cerebellar regions were included) between cognitively normal older adults and aMCI subjects at risk of AD, as well as aMCI subjects at risk of PD. Our objective was to identify default mode network regions that show significant atrophy in the aMCI subjects (irrespective of disease origins, i.e., AD or PD) compared with cognitively normal older adults. This goal will identify common mechanisms that can be targeted for relief of similar amnestic symptoms in the future. A supplementary objective was to evaluate neuropathologic vulnerabilities associated with APOE-ε4 carrier status in individuals with aMCI.

Recently, we investigated the differences in morphometric measurements due to variations in T1 imaging protocols in Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Progressive Parkinson’s Markers Initiative (PPMI) [27–30]. These are public databases with imaging data for AD and PD. They provide an excellent opportunity to test hypotheses of pathological and systemic overlap in the two diseases. One challenge is the different imaging parameters in the two databases that may introduce a systematic bias and increased variability, thus negatively impacting the comparisons. We have identified data from the same scanner manufacturer with identical imaging parameters in the two databases that will be leveraged for this study.

2. Methods

2.1. ADNI and PPMI databases

The ADNI (adni.loni.usc.edu) database was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD (www.adni-info.org).

The PPMI database (www.ppmi-info.org) was used to assess patients with PD. Only those subjects who were acquired with the following identical parameters in both ADNI and PPMI were selected: Siemens (Erlangen, Germany) scanner, 3T, TR/TE = 2300/2.98 ms, TI = 900 ms, resolution = 1 × 1 mm², and slice thickness = 1–1.2 mm. Morphometric measurements especially with FreeSurfer [31] are known to be unaffected when slice thickness = 1–1.3 mm.

2.2. Subject selection and clinical phenotyping

All scans were baseline scans. ADNI comprises older adults at risk of AD, who are further subdivided into early MCI (EMCI), MCI, and late MCI (LMCI). Although the MCI classification is an older classification scheme, LMCI subjects have more severe cognitive deficits, less likely evident in early PD subjects from PPMI. Therefore, we restricted our sample to EMCI participants from ADNI but included all PD subjects from PPMI.

Despite the large number of neuropsychological assessments in ADNI and PPMI, there is very little overlap [32–39]. Memory proficiency is assessed using delayed recall verbal learning tests: the Auditory Verbal Learning Test in ADNI and the Hopkins Verbal Learning Test in PPMI [40,41]. Both tests provide similar outcomes [42,43]. We classified patients as aMCI based on delayed recall scores of the Auditory Verbal Learning Test in ADNI and of the Hopkins Verbal Learning Test in PPMI. To accomplish this, the scores from the two assessments were z-transformed to account for differences in the scoring systems. Within ADNI, the mean result was subtracted from the individual score and then divided by the standard deviation of the scores in the cognitively normal controls. Identical transformation was performed in PPMI. Subjects with $z < -0.5$, that is, half a standard deviation below normative sample, were considered to be aMCI. ADNI uses a similar definition based on delayed recall to define EMCI subjects.

A total of 231 subjects were identified that completed Hopkins Verbal Learning Test/Auditory Verbal Learning Test assessments, had documented APOE-ε4 gene status, and completed a similar imaging protocol. All patients had
CSF biomarkers analyzed in the same run (to minimize batch effects). We repeated the above comparisons in amyloid-negative controls (n = 49, 9 APOE-ε4), amyloid-positive MCI (n = 25, 14 APOE-ε4 carriers), and PD subjects (n = 28, 4 APOE-ε4 carriers), to obtain phenotypically similar but pathologically distinct groups. The prevalence of APOE-ε4 in PD is much lower than in AD in this study.

2.3. Image analysis and statistical considerations

For the default mode network, we included the middle temporal cortex, parahippocampal gyrus, precuneus, posterior cingulate, inferior parietal regions, medial orbitofrontal regions, and hippocampus (Fig. 1A). We applied the standard FreeSurfer (v5.1.0) pipeline comprising intensity normalization, skull tissue removal, tissue segmentation, resampling to a $1 \times 1 \times 1 \text{mm}^3$ resolution, and registration to the standard FreeSurfer brain (fsaverage) [31]. Briefly, this pipeline includes removal of nonbrain tissue using a hybrid watershed/surface deformation procedure, automated Talairach transformation, segmentation of the subcortical white matter and deep gray matter volumetric structures, intensity normalization [44,45], tessellation of the gray/white matter boundary, automated topology correction, and surface deformation following intensity gradients to optimally place the gray/white and gray/cerebrospinal fluid borders at the location where the greatest shift in intensity defines the transition to the other tissue class [46,47]. No manual editing was performed. However, 10% of the data were randomly sampled and visually inspected to ensure accurate segmentation.

We applied two linear regression models. The first evaluated association of regional atrophy in the default mode network regions and aMCI status. This association was adjusted for age and gender. Comparisons were made between cognitively normal controls and the aMCI group comprising both ADNI and PPMI together, irrespective of disease pathology. Post hoc, two separate comparisons between cognitively normal controls and the aMCI group with reduced CSF amyloid, and PD, were performed. The second regression model was used to assess regional atrophy as function of APOE-ε4 allele status while adjusting for age and gender within each group.

![Fig. 1. Cortical atrophy in aMCI.](image-url)

(A) Regions of the default mode network tested in this study. Right and left side thickness and volumes were combined. The green area near the temporal lobe is representative of the hippocampus. (B) The middle temporal lobe and the parahippocampal gyrus showed significant thinning in the aMCI phenotype compared with the cognitively normal individuals. (C) The thickness reductions in the aMCI subjects were observed regardless of disease origins. Amnestic MCI subjects from ADNI and PPMI both show decreased cortical thickness in the middle temporal gyrus and parahippocampal gyrus. (D) Although hippocampal atrophy was not significant, the slope of the relationship between hippocampal volume and age was significantly steeper in the aMCI individuals (golden ○) compared with the cognitively normal group (black ●). (E) This relationship in (D) was maintained even when the cohort was refined to include only amyloid-negative controls, and amyloid-positive AD-MCI subject and amyloid-negative PD-MCI subjects. * Denotes mean values for each group, Normal, AD, and PD. Abbreviations: AD, Alzheimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; aMCI, amnestic mild cognitive impairment; MCI, mild cognitive impairment; PD, Parkinson’s disease; PPMI, Progressive Parkinson’s Markers Initiative.
For the above seven regions and two evaluations (group difference and interaction with age while adjusting for age and gender), a correction for multiple comparisons was applied separately for each regression model at a false discovery rate (FDR) of 0.1. Significance was evaluated using the Benjamini Hochberg procedure. All \( P \) values reported in the text are original uncorrected \( P \) values for regions that satisfied the FDR criteria for significance. FDR-based significance is indicated for these regions by an “*” in the tables with statistical results. Effect sizes are also reported (0.2 = small, 0.5 = medium, 0.8 = large [48]). Hippocampal volume comparisons were adjusted for brain size using intracranial volume (eTIV in FreeSurfer). To confirm that the differences were not only due to a large AD-aMCI sample size, we show the morphometric measurements with the aMCI groups separated by disease designation.

3. Results

3.1. Demographics

We identified 109 controls (76 men, age = 75 ± 5 years) from ADNI and 28 controls from PPMI (18 men, age = 70 ± 4 years). Also, 61 AD-MCI (47 men, age = 75 ± 6 years) and 33 PD-MCI (22 men, age = 70 ± 4 years) subjects were identified. AD-MCI PPMI subjects were significantly younger (\( P < .01 \)). All outcomes were adjusted for age and gender. The incidence of APOE-ε4 in the cognitively normal older adults is similar in ADNI (25%, n = 27) and PPMI (28%, n = 8) but higher in the AD-MCI group (26%, n = 24) compared with the PD-MCI group (12%, n = 4).

3.2. Anatomical differences in cognitively normal older adults and aMCI

Individuals with aMCI from both ADNI and PPMI had reduced cortical thickness in default mode network regions, with steeper negative correlation of age and hippocampal volume. Fig. 1B illustrates the regions of the default mode network that were significantly different between controls and aMCI groups. Table 1 outlines statistical differences, where reductions in the parahippocampal gyrus and the middle temporal region are greatest in the aMCI phenotype (\( P = .007, P = .005, \) and \( P = .009, \) respectively). Amnestic MCI individuals with presumed AD and PD showed a decrease in cortical thickness (Fig. 1C) in the middle temporal and parahippocampal gyrus. Middle temporal gyral thickness values in the cognitively normal, aMCI-ADNI, and aMCI-PPMI participants were 2.71 ± 0.12 mm, 2.66 ± 0.16 mm, 2.68 ± 0.10 mm, respectively. Values for the parahippocampal gyrus were 2.62 ± 0.24 mm, 2.53 ± 0.27 mm, and 2.50 ± 0.29 mm, respectively, consistent with the reduced cortical thickness in aMCI not being driven simply by disease classification (e.g., AD or PD). No significant relationship was observed between gender and cortical thickness.

Compared with the cognitively normal older adults, the trajectory of hippocampal volume decline with age was significantly faster (\( P = .007 \)) in the aMCI group (Fig. 1D). Pearson’s correlation value, \( r \), for hippocampal volume and age was \( -0.49 \) in the aMCI group compared with \( -0.27 \) in the cognitively normal individuals. When amyloid-positive control subjects and amyloid-negative aMCI subjects were excluded, no group differences in subcortical volumes were observed. However, the

| Regions                                      | Effect size | \( P \) value | FDR significance |
|----------------------------------------------|-------------|---------------|------------------|
| Cognitively normal older adults versus aMCI  |
| Medial orbitofrontal                         | 0.23        | .13           |                  |
| Middle temporal                              | 0.31        | .009          | *                |
| Parahippocampial                             | 0.38        | .005          | *                |
| Hippocampus                                  | 0.08        | .05           |                  |
| Inferior parietal                            | 0.16        | .21           |                  |
| Posterior cingulate                          | 0.16        | .42           |                  |
| Precuneus                                    | 0.27        | .01           |                  |
| \( r \) (cognitively normal)                 |             |               |                  |
| \( r \) (amnestic MCI phenotype)             |             |               |                  |
| Age interactions                             |             |               |                  |
| Medial orbitofrontal                         | 0.07        | 0.07          | .99              |
| Middle temporal                              | -0.19       | -0.16         | .99              |
| Parahippocampial                             | -0.09       | -0.16         | .52              |
| Hippocampus                                  | -0.27       | -0.49         | .007             |
| Inferior parietal                            | -0.3        | -0.3          | .75              |
| Posterior cingulate                          | -0.01       | -0.13         | .37              |
| Precuneus                                    | -0.37       | -0.5          | .13              |

Abbreviations: FDR, false discovery rate; MCI, mild cognitive impairment.

NOTE: Bold values denote significance at \( P = .05 \) value that is uncorrected using FDR. * Indicates values that are significant after correcting for multiple comparisons using FDR.
estimated rate of hippocampus atrophy was significantly steeper \((P = .007)\) in the amyloid-positive aMCI group (Fig. 1E). This finding is similar to Fig. 1D, where amyloid positivity was not considered. Pearson’s correlation value, \(r\), for hippocampal volume and age was \(-0.53\) in the aMCI group compared with \(-0.11\) in the cognitively normal individuals.

### 3.3. Anatomical differences in APOE-\(\varepsilon\)4 carriers

Cognitively normal APOE-\(\varepsilon\)4 carriers \((n = 35)\) showed significantly reduced thickness in the parahippocampal gyrus with increasing age, and this survived FDR correction (Table 2 and depicted in Fig. 2A; \(r = -0.51, P = .0004\)). No relationship between parahippocampal gyrus thickness and age of noncarriers of APOE-\(\varepsilon\)4 was evident.

In the amyloid-negative controls (CSF-A\(\beta\)\(_{42}\) >192 pg/mL), the APOE-\(\varepsilon\)4 carriers had significantly greater cortical thickness in the inferior parietal, middle temporal gyrus, and precuneus regions (Fig. 2B, inferior parietal, \(P = .002\), effect size 1.18; middle temporal gyrus, \(P = .005\), effect size 0.88; and precuneus, \(P = .01\), effect size 1.08).

In the aMCI subjects, the middle temporal gyrus, inferior parietal region, and the precuneus had significantly reduced thickness in the 28 APOE-\(\varepsilon\)4 carriers compared with the noncarriers (Fig. 3A). Thickness values in the middle temporal, inferior parietal, and the precuneal regions in the APOE-\(\varepsilon\)4 carriers were 2.19 ± 0.12 mm, 2.61 ± 0.14, and 2.12 ± 0.13 mm, and 2.31 ± 0.10 mm, 2.69 ± 0.13 mm and 2.23 ± 0.12 mm in noncarriers (Table 2), respectively. A post hoc analysis (Fig. 3B) found that cortical thickness differences in the aMCI APOE-\(\varepsilon\)4 carriers

### Table 2

| Regions                              | Effect size | \(P\) value | FDR significance |
|--------------------------------------|-------------|--------------|------------------|
| Controls, APOE-\(\varepsilon\)4 carriers versus noncarriers |             |              |                  |
| Medial orbitofrontal                 | 0.08        | .71          |                  |
| Middle temporal                      | 0.20        | .16          |                  |
| Parahippocampal                      | 0.00        | .83          |                  |
| Hippocampus                          | 0.11        | .69          |                  |
| Inferior parietal                    | 0.50        | .01          |                  |
| Posterior cingulate                  | 0.23        | .26          |                  |
| Precuneus                            | 0.23        | .08          |                  |
| Age interactions                     |             |              |                  |
| Medial orbitofrontal                 | 0.13        | -0.02        | .35              |
| Middle temporal                      | -0.06       | -0.38        | .03              |
| Parahippocampal                      | 0.14        | -0.51        | .0004            |
| Hippocampus                          | -0.18       | -0.48        | .18              |
| Inferior parietal                    | -0.21       | -0.46        | .75              |
| Posterior cingulate                  | 0.05        | -0.16        | .28              |
| Precuneus                            | -0.29       | -0.53        | .17              |
| aMCI, APOE-\(\varepsilon\)4 carriers versus noncarriers |             |              |                  |
| Medial orbitofrontal                 | 0.28        | .3           |                  |
| Middle temporal                      | 0.57        | .009         | *                |
| Parahippocampal                      | 0.00        | .87          |                  |
| Hippocampus                          | 0.03        | .79          |                  |
| Inferior parietal                    | 1.00        | .0001        | *                |
| Posterior cingulate                  | 0.60        | .03          |                  |
| Precuneus                            | 0.84        | .0002        | *                |
| Age interactions                     |             |              |                  |
| Medial orbitofrontal                 | -0.02       | 0.31         | .16              |
| Middle temporal                      | -0.09       | -0.23        | .33              |
| Parahippocampal                      | -0.09       | -0.34        | .34              |
| Hippocampus                          | -0.47       | -0.56        | .53              |
| Inferior parietal                    | -0.26       | -0.3         | .54              |
| Posterior cingulate                  | -0.06       | -0.25        | .54              |
| Precuneus                            | -0.45       | -0.59        | .32              |

Abbreviations: aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein; FDR, false discovery rate.

NOTE. Bold values denote significance at \(P = .05\) value that is uncorrected using FDR. * Indicates values that are significant after correcting for multiple comparisons using FDR.
carriers were apparent in both ADNI and PPMI cohorts. ADNI aMCI participants with APOE-ε4 had reduced cortical thickness values in the middle temporal gyrus, inferior parietal region, and the precuneus: 2.59 ± 0.16 mm, 2.18 ± 0.16 mm, and 2.11 ± 0.14 mm, versus 2.70 ± 0.15 mm, 2.28 ± 0.10 mm, and 2.20 ± 0.11 mm in APOE-ε4 noncarriers, respectively. PPMI aMCI participants with APOE-ε4 also had reduced cortical thickness values in these same regions: 2.68 ± 0.10 mm, 2.35 ± 0.09 mm, and 2.27 ± 0.12 mm, versus 2.68 ± 0.15 mm, 2.29 ± 0.05 mm, and 2.21 ± 0.07 mm in noncarriers. Note that there were only four APOE-ε4-positive patients with PD, but they had markedly lower cortical thickness in the inferior parietal regions. In the amyloid-positive MCI subjects in ADNI and PD subjects from PPMI, precuneus region was significantly thinner (P < .001, effect size = 0.92) compared with healthy amyloid-negative control subjects. Again, this difference was observed in both AD-MCI and PD-MCI subjects as shown in Fig. 3C.

4. Discussion

We show that across two distinct neurodegenerative disorders, patients with clinical symptoms of aMCI localize to common regions involved in the default mode network. Furthermore, the APOE-ε4 carriers from both AD and PD populations showed similar atrophy patterns when compared with cognitively normal controls. These findings are consistent, even when accounting for amyloid status and lend support to the hypothesis that clinical symptoms of memory dysfunction converge on default mode network–related regions. That is, significantly reduced thickness of the middle temporal and parahippocampal cortices are evident in aMCI and aMCI-PD patients with lower verbal memory scores. Together, the estimated rate of hippocampal volume decline...
is faster than that of cognitively normal controls. Although these findings are in agreement with multiple studies [49–51] linking cortical atrophy to MCI status, especially the middle temporal gyrus, we extend these findings beyond studies of patients with AD and emphasize that these findings are consistent in patients with PD. Patients with a similar aMCI phenotype have reductions in cortical thickness in the same regions. These results emphasize the role of network-based changes and memory-related symptoms that span clinicopathologic classifications.

Using CSF-Aβ42 as a marker of aMCI patients with concomitant AD pathology and comparing this cohort to PD patients with a motor-confirmed diagnosis, we are able to emphasize the role of hippocampal volume as a marker of aMCI status between groups. Very few studies have shown hippocampal atrophy in PD, but hippocampal atrophy has been reported in advanced PD patients with dementia [52,53]. In this analysis, we show that middle temporal and parahippocampal regions are most different as compared with healthy controls, where aMCI participants with presumed AD pathology had an estimated 1.7% smaller mesial temporal cortical thickness with an effect size of 3.59, and patients with PD had 2.8% lower thickness, with effect size = 0.48. In the remaining default motor network regions, the percent reductions ranged from 0.8% to 1.6% but were not significant. Taken together, these results emphasize that faster rates of hippocampal atrophy and thinning in the mesial temporal lobe regions in PD may be a biomarker of an aMCI subgroup and should be further validated.

Our results emphasize that the effect of APOE-e4 on thickness of the precuneus is consistent across AD and PD groups. The precise role of APOE-e4 in precuneal pathology is still not known, but it is clear that functional connectivity in APOE-e4–positive patients is reduced and may emphasize the larger role of APOE-e4 on memory-based networks, with convergence on the precuneus. Functional magnetic resonance imaging studies emphasize that default mode network deactivation, during memory tasks, does not occur in APOE-e4–positive patients with AD. Similarly, blood flow changes in aMCI patients with AD localize to this region, the posterior cingulate, and the default mode network. What predisposes APOE-e4–positive individuals to AD-related pathology is not known, but our results emphasize that there are differences between individuals with low CSF-Aβ42 versus normal levels. Those with normal CSF-Aβ42 levels actually have greater cortical thickness, a finding that replicates previous studies of higher IQ and educational achievement in APOE-e4–positive patients [54,55].

Of course, despite our best attempts at comparing patients with similar pathologic process, that is, accounting for CSF-Aβ42 levels, it is clear that systematic changes to CSF amyloid differ between PD and AD. Although patients with PD may have amyloid plaques at autopsy, the frequency of these is low, and higher CSF amyloid levels reflect this difference. Previous studies emphasize that using conventional cutoff criteria for amyloid positivity does not provide informative assessments of amyloid status in PD. It is likely that the neuropathological cascade that results in amyloid accumulation differs between PD and AD. Our study used the delayed recall scores from verbal learning tests to define aMCI individuals. This definition may not adequately capture the aMCI phenotype and is limited by the lack of common tests between the two databases and likely influenced by the varying degree of vascular pathology as well as medication history of the individuals. One approach to circumvent the differences in cognitive batteries would be to select similar tests and z-scoring them using the control individuals within each database. In summary, this work supports the hypothesis that converging changes to default mode network regions, especially the mesial temporal lobe and precuneus, are shared in patients with AD and PD. While the pathologic basis for changes to this network may differ, amnestic symptoms not only localize here but also are impacted by APOE-e4 and CSF-amyloid levels in patients with AD. Patients with aMCI have greater rates of hippocampal atrophy. Future studies on mechanisms of network-level susceptibility despite diverse disease states may inform common pathways of degeneration.

Acknowledgments

Data used in preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI: www.ppmi-info.org) and Alzheimer’s Disease Neuroimaging Initiative (ADNI) databases (adni.loni.usc.edu). As such, the investigators within PPMI and ADNI contributed to the design and implementation of both databases, and/or provided data, but did not participate in analysis or writing of this report. A complete list of PPMI study investigators can be found at www.ppmi-info.org/authorslist/. A complete listing of ADNI investigators can be found at www.adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Arclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;
Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GSK GlaxoSmithKline, Lilly, Lundbeck, Merck, MSD Meso Scale Discovery, Pfizer Inc., Piramal, Roche, Servier, and UCB.

Grant support: S.R. received grant support from Biomarkers Across Neurodegenerative Disease from Alzheimer’s Association, Michael J Fox Foundation, and W. Garfield Weston Foundation, DC: R01NS097783-01.

**RESEARCH IN CONTEXT**

1. Systematic review: This work was performed for the Biomarkers Across Neurodegenerative Disease initiative from the Alzheimer’s Association, Fox Foundation, and Weston Brain Institute to identify overlapping mechanisms in distinct neurodegenerative diseases. Search terms include “default mode network,” “Alzheimer’s disease,” “Parkinson’s disease,” “cortical thickness,” “functional MRI,” “mMCI,” etc.

2. Interpretation: We observed common regional vulnerability in both amnestic Alzheimer’s disease (AD) and Parkinson’s disease (PD) individuals. The genetic risk factor for AD (APOE-ε4), although rare in PD, was associated with similar cortical thinning in both diseases. This is the first study to assess AD and PD individuals together.

3. Future directions: Functional magnetic resonance imaging of the common regions will determine common and unique connectivity patterns in amnestic AD and PD individuals. Further investigation is warranted in PD ε4 carriers to confirm our results due to their low prevalence. This work could lay the groundwork to identify and manage converging pathological mechanisms in disparate disorders.

**References**

[1] James BD, Boyle PA, Buchman AS, Barnes LL, Bennett DA. Life space and risk of Alzheimer disease, mild cognitive impairment, and cognitive decline in old age. Am J Geriatr Psychiatry 2011;19:961–9.

[2] Finch CE, Cohen DM. Aging, metabolism, and Alzheimer disease: Review and hypotheses. Exp Neurol 1997;143:82–102.

[3] Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain 1991;114:2283–301.

[4] Zipp F, Aktas O. The brain as a target of inflammation: Common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006;29:518–27.

[5] Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5:863–73.

[6] Harhangi BS, De Rijk MC, Van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54:1272–6.

[7] Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neuro 2013; 9:106–18.

[8] Bookeheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 2000; 343:450–6.

[9] Brooks DJ. Imaging amyloid in Parkinson’s disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 2009;24:S742–7.

[10] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small G, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–3.

[11] Monsell SE, Besser LM, Heller KB, Checkoway H, Litvan I, Kukull WA. Clinical and pathologic presentation in Parkinson’s disease by apolipoprotein e ε4 allele status. Parkinsonism Relat Disord 2014;20:503–7.

[12] Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79:458–61.

[13] Koller WC, Glatt SL, Hubble JP, Paolo A, Tröster AI, Schmidt K, et al. Apolipoprotein E genotypes in Parkinson’s disease with and without dementia. Ann Neurol 1995;37:242–5.

[14] Camicioni R, Rajput A, Rajput M, Reece C, Payami H, Hao C, et al. Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: Relationship to dementia and hallucinations. Mov Disord 2005;20:989–94.

[15] Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 2006;59:512–9.

[16] Tapiola T, Pirritiil T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, et al. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neurosci Lett 2000; 280:119–22.

[17] Jensen M, Schröder J, Blomberg M, Engvall B, Pantel J, Ida N, et al. Cerebrospinal fluid Ab42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann Neurol 1999; 45:504–11.

[18] Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D’Angelo G, et al. APOEε4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Ab42. J Neurosci 2010; 30:17035–40.

[19] Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. Proc Natl Acad Sci U S A 2009;106:7209–14.

[20] Jones DT, Machulda MM, Vemuri P, McDade EM, Zeng G, Senjem ML, et al. Age-related changes in the default mode network.
are more advanced in Alzheimer disease. Neurology 2011;77:1524–31.
[21] Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: Evidence from a partial correlation network analysis. Neuroimage 2008;42:1178–84.
[22] van Eimeren T, Monchi O, Ballanger B, Strafella AP. Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study. Arch Neurol 2009;66:877–83.
[23] Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: Evidence from functional MRI. Proc Natl Acad Sci U S A 2004;101:4367–42.
[24] Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709–17.
[25] Delaveau P, Salgado-Pineda F, Fossati P, Witjas T, Azulay JP, Blin O. Dopaminergic modulation of the default mode network in Parkinson’s disease. Eur Neuropsychopharmacol 2010;20:784–92.
[26] Krajcovicova L, Mikl M, Marecek R, Rektorova I. The default mode network integrity in patients with Parkinson’s disease is levodopa equivalent dose-dependent. J Neural Transm 2012;119:443–54.
[27] Rane S, Plassard A, Landman BA, Claassen DO, Donahue MJ. Comparison of Cortical and Subcortical Measurements in Normal Older Adults across Databases and Software Packages. J Alzheimer’s Dis Rep 2017;1:59–70.
[28] Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer’s De ment 2005;1:55–66.
[29] Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685–91.
[30] Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The parkinson progression marker initiative (PPMI). Prog Neurobiol 2011;95:629–35.
[31] Delaveau P, Salgado-Pineda F, Fossati P, Witjas T, Azulay JP, Blin O. Dopaminergic modulation of the default mode network in Parkinson’s disease. Eur Neuropsychopharmacol 2010;20:784–92.
[32] Krajcovicova L, Mikl M, Marecek R, Rektorova I. The default mode network integrity in patients with Parkinson’s disease is levodopa equivalent dose-dependent. J Neural Transm 2012;119:443–54.
[33] Rane S, Plassard A, Landman BA, Claassen DO, Donahue MJ. Comparison of Cortical and Subcortical Measurements in Normal Older Adults across Databases and Software Packages. J Alzheimer’s Dis Rep 2017;1:59–70.
[34] Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer’s De ment 2005;1:55–66.
[35] Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685–91.
[36] Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The parkinson progression marker initiative (PPMI). Prog Neurobiol 2011;95:629–35.
[37] Fischl B. FreeSurfer. Neuroimage 2012;62:774–81.
[38] Henderson JM, Lu Y, Wang S, Cartwright H, Halliday GM. Olfactory deficits and sleep disturbances in Parkinson’s disease: a case–control survey. J Neurol Neurosurg Psychiatry 2003;74:956–8.
[39] Crowe SF. Does the letter number sequencing task measure anything more than digit span? Assessment 2000;7:113–7.
[40] Benedikt HB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Test Reliability. Clin Neuropsychol 1998;12:43–55.
[41] Schmidt M. Rey Auditory Verbal Learning Test: A Handbook. Los Angeles, CA: Western Psychological Services; 1996.
[42] Lacritz LH, Callum CM, Weiner MF, Rosenberg RN. Comparison of the hopkins verbal learning test-revised to the California verbal learning test in Alzheimer’s disease. Appl Neuropsychol 2001;8:180–4.
[43] Stallings G, Boake C, Sherer M. Comparison of the California verbal learning test and the Rey auditory verbal learning test in head-injured patients. J Clin Exp Neuropsychol 1995;17:706–12.
[44] Ségonne F, Dale AM, Busa E, Glessner M, Salat D, Hahn HK, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004;22:1060–75.
[45] Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–55.
[46] Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. Medical Imaging. IEEE Trans 1998;17:87–97.
[47] Ségonne F, Pacheco J, Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. Medical Imaging. IEEE Trans 2007;26:518–29.
[48] Cohen J. Statistical power analysis. Curr Dir Psychol Sci 1992; 1:98–101.
[49] Bell-McGinty S, Lopez OL, Meltzer CC, Scanlon JM, Whyte EM, DeKosky ST, et al. Differential cortical atrophy in subgroups of mild cognitive impairment. Arch Neurol 2005;62:1393–7.
[50] Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008; 70:512–20.
[51] Karas G, Shuimer J, Goekoop R, Van Der Flier W, Rombouts SA, Vrenken H, et al. Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. Am J Neuroradiol 2008;29:344–9.
[52] Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson’s disease is associated with hippocampal atrophy. Mov Disord 2003;18:784–90.
[53] Brück A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson’s disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004;75:1467–9.
[54] Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ. Intelligence and event-related potentials for young female human volunteer apolipoprotein E ε4 and non-ε4 carriers. Neurosci Lett 2000;294:179–81.
[55] Hubacek JA, Pitha J, Škodová Z, Adámková V, Lánská V, Poledne R. A possible role of apolipoprotein E polymorphism in predisposition to higher education. Neuropsychobiology 2001;43:200–3.